Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -99.98% | -145.30% | -207.60% | -221.65% | -42.74% |
| Total Depreciation and Amortization | -74.20% | -36.15% | 34.26% | 196.40% | 696.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9,996.10% | 621.99% | 405.36% | 636.81% | 62.25% |
| Change in Net Operating Assets | 405.56% | -134.71% | -147.16% | -128.40% | -87.68% |
| Cash from Operations | -8.57% | -63.62% | -120.47% | -338.23% | -157.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -168.56% | -- | -- | -- | -- |
| Total Debt Issued | 155.06% | 79.45% | 84.63% | 114.00% | 36.68% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | 86.51% | 36.55% | 40.60% | 117.22% | 245.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 316.79% | 108.35% | -789.71% | -210.82% | -640.00% |